Cargando…

Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm

Iron plays a key role in many physiological processes; cells need a very exact quantity of iron. In patients with inflammatory bowel disease, anaemia is a unique example of multifactorial origins, frequently being the result of a combination of iron deficiency and anaemia of chronic disease. The mai...

Descripción completa

Detalles Bibliográficos
Autores principales: Gargallo-Puyuelo, Carla J., Alfambra, Erika, García-Erce, Jose Antonio, Gomollon, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316243/
https://www.ncbi.nlm.nih.gov/pubmed/30544934
http://dx.doi.org/10.3390/nu10121959
_version_ 1783384483383214080
author Gargallo-Puyuelo, Carla J.
Alfambra, Erika
García-Erce, Jose Antonio
Gomollon, Fernando
author_facet Gargallo-Puyuelo, Carla J.
Alfambra, Erika
García-Erce, Jose Antonio
Gomollon, Fernando
author_sort Gargallo-Puyuelo, Carla J.
collection PubMed
description Iron plays a key role in many physiological processes; cells need a very exact quantity of iron. In patients with inflammatory bowel disease, anaemia is a unique example of multifactorial origins, frequently being the result of a combination of iron deficiency and anaemia of chronic disease. The main cause of iron deficiency is the activity of the disease. Therefore, the first aim should be to reach complete clinical remission. The iron supplementation route should be determined according to symptoms, severity of anaemia and taking into account comorbidities and individual risks. Oral iron can only be used in patients with mild anaemia, whose disease is inactive and who have not been previously intolerant to oral iron. Intravenous iron should be the first line treatment in patients with moderate-severe anaemia, in patients with active disease, in patients with poor tolerance to oral iron and when erythropoietin agents or a fast response is needed. Erythropoietin is used in a few patients with anaemia to overcome functional iron deficiency, and blood transfusion is being restricted to refractory cases or acute life-threatening situations.
format Online
Article
Text
id pubmed-6316243
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63162432019-01-08 Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm Gargallo-Puyuelo, Carla J. Alfambra, Erika García-Erce, Jose Antonio Gomollon, Fernando Nutrients Review Iron plays a key role in many physiological processes; cells need a very exact quantity of iron. In patients with inflammatory bowel disease, anaemia is a unique example of multifactorial origins, frequently being the result of a combination of iron deficiency and anaemia of chronic disease. The main cause of iron deficiency is the activity of the disease. Therefore, the first aim should be to reach complete clinical remission. The iron supplementation route should be determined according to symptoms, severity of anaemia and taking into account comorbidities and individual risks. Oral iron can only be used in patients with mild anaemia, whose disease is inactive and who have not been previously intolerant to oral iron. Intravenous iron should be the first line treatment in patients with moderate-severe anaemia, in patients with active disease, in patients with poor tolerance to oral iron and when erythropoietin agents or a fast response is needed. Erythropoietin is used in a few patients with anaemia to overcome functional iron deficiency, and blood transfusion is being restricted to refractory cases or acute life-threatening situations. MDPI 2018-12-11 /pmc/articles/PMC6316243/ /pubmed/30544934 http://dx.doi.org/10.3390/nu10121959 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Gargallo-Puyuelo, Carla J.
Alfambra, Erika
García-Erce, Jose Antonio
Gomollon, Fernando
Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm
title Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm
title_full Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm
title_fullStr Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm
title_full_unstemmed Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm
title_short Iron Treatment May Be Difficult in Inflammatory Diseases: Inflammatory Bowel Disease as a Paradigm
title_sort iron treatment may be difficult in inflammatory diseases: inflammatory bowel disease as a paradigm
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316243/
https://www.ncbi.nlm.nih.gov/pubmed/30544934
http://dx.doi.org/10.3390/nu10121959
work_keys_str_mv AT gargallopuyuelocarlaj irontreatmentmaybedifficultininflammatorydiseasesinflammatoryboweldiseaseasaparadigm
AT alfambraerika irontreatmentmaybedifficultininflammatorydiseasesinflammatoryboweldiseaseasaparadigm
AT garciaercejoseantonio irontreatmentmaybedifficultininflammatorydiseasesinflammatoryboweldiseaseasaparadigm
AT gomollonfernando irontreatmentmaybedifficultininflammatorydiseasesinflammatoryboweldiseaseasaparadigm